RxDoctor Payments Data

Sean Kohl, MD

Family Medicine · Albion, NENPI 1629068325

Payments from drug & device makers

$937in general payments, 2019–2025

Across 30 payments — averaging $31.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Musculoskeletal Transplant Foundation Inc.$567
  • Organogenesis Inc.$84
  • AbbVie$71
  • Novo Nordisk$56
  • KCI USA, Inc.$39
  • Mylan Specialty L.p.$28
  • plus $92 from 5 others

What the payments were for

  • Food & beverage$937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$937 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$7,587
Medicare patients
26
Services billed
100

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$82,620
Humira PenAdalimumab11$80,451
OzempicSemaglutide53$51,878
XareltoRivaroxaban69$38,682
JanuviaSitagliptin Phosphate62$26,931
Tresiba Flextouch U-200Insulin Degludec20$25,840
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$24,304
FarxigaDapagliflozin Propanediol29$21,035
JardianceEmpagliflozin21$20,016
VraylarCariprazine Hcl23$16,475
Fiasp FlextouchInsulin Aspart (Niacinamide)13$14,798
Praluent PenAlirocumab16$13,330
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog32$11,478
MounjaroTirzepatide11$11,473
RybelsusSemaglutide12$11,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$56$63,21765 claims
AbbVieVraylar$71$16,47523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Albion

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →